W. Franklin - Concepedia

Author

W. Franklin

Also Known As

FRANCIS C. LOWELL, W A Franklin, W FRANKLIN, W Franklin, W. A. Franklin, W. Franklin, W.A Franklin, W.A. Franklin, WA Franklin, WILLIAM FRANKLIN

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of Colorado Denver University of California, Davis SWOG Cancer Research Network University of Colorado Cancer Center University of Colorado Health

About

W. Franklin is an author at University of Colorado Denver specializing in medicine, oncology, and lung cancer.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	12	13	766
2	Cell Biology	3	3	402
3	Health Sciences	2	2	49
4	Allergy	1	1	44
5	Diabetes	1	1	19

W. Franklin

Publications

882

Citations

H-Index

Page 1

	Year	Citations
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell lines Glen J. Weiss, Lynne Bemis, Eri Nakajima, Annals of Oncology Egfr ExpressionOncologyMedicinePathologyCancer Genomics	2008	240
Epidermal growth factor receptor expression, signal pathway, and inhibitors in non–small cell lung cancer P BUNNJR, W. Franklin Seminars in Oncology OncologyCell Lung CancerSignal PathwayMedicineCancer Cell Biology	2002	141
Cytopathological analysis of sputum in patients with airflow obstruction and significant smoking histories. Timothy C. Kennedy, S Proudfoot, W. Franklin, PubMed Severe DysplasiaAdvanced Lung DiseaseAirflow ObstructionCytopathological AnalysisPathology	1996	103
Amifostine (WR-2721) shortens the engraftment period of 4- hydroperoxycyclophosphamide-purged bone marrow in breast cancer patients receiving high-dose chemotherapy with autologous bone marrow support E.J. Shpall, L. Hami, W. Franklin, Blood	1994	62
Analysis of DNA ploidy and proliferative activity in relation to histology and N-myc amplification in neuroblastoma. Susan L. Cohn, Alfred Rademaker, Helen R. Salwen, PubMed	1990	54
Gefitinib (ZD1839) therapy for advanced bronchioloalveolar lung cancer (BAC): Southwest Oncology Group (SWOG) Study S0126 Howard West, W. Franklin, Paul H. Gumerlock, Journal of Clinical Oncology Tumor BiologyGefitinib TherapyMedicineCancer ManagementSouthwest Oncology Group	2004	47
Epidermal growth factor receptor gene copy number and protein level are not associated with outcome of non-small-cell lung cancer patients treated with chemotherapy Rafał Dziadziuszko, Bente Holm, B. G. Skov, Annals of Oncology MedicinePathologyProtein LevelBronchial NeoplasmCancer Genomics	2006	46
UNRECOGNIZED AIRWAY OBSTRUCTION ASSOCIATED WITH SMOKING: A PROBABLE FORERUNNER OF OBSTRUCTIVE PULMONARY EMPHYSEMA W. Franklin, Francis C. Lowell Annals of Internal Medicine AsthmaPulmonary CareInflammatory Lung DiseaseAdvanced Lung DiseaseLung Inflammation	1961	44
Mutational analysis of <i>K-RAS</i> and <i>EGFR</i> implicates <i>K-RAS</i> as a resistance marker in the Southwest Oncology Group (SWOG) trial S0126 of bronchioalveolar carcinoma (BAC) patients (pts) treated with gefitinib Paul H. Gumerlock, William Holland, H. Chen, Journal of Clinical Oncology Codon 858Nsclc AdenocarcinomaPathologyCancer BiologyTumor Biology	2005	35
A randomized study of fluorescence bronchoscopy versus white-light bronchoscopy for early detection of lung cancer in high risk patients Timothy C. Kennedy, F. R. Hirsch, Y E Miller, Lung Cancer Medical ImagingFluorescence BronchoscopyCancer ScreeningRandomized StudyMedicine	2000	30

Page 1